Spyre Therapeutics (NASDAQ: SYRE) Soars on Positive Phase 2 Ulcerative Colitis Trial Results

Font: Financial Modeling Prep  • Apr 14, 2026

• Spyre Therapeutics (NASDAQ: SYRE) announced successful Phase 2 SKYLINE trial results for its drug candidate SPY001, targeting moderate-to-severe ulcerative colitis.
• The trial achieved its primary goal with a statistically significant 9.2-point reduction in the Robart's Histopathology Index (RHI) score, alongside key secondary goals including 40% clinical remission.
• Deutsche Bank raised its price target for Spyre Therapeutics to $88.00, indicating a potential 39.09% upside, which contributed to a 23.36% single-day stock surge and a market capitalization of approximately $3.82 billion.

Spyre Therapeutics (NASDAQ: SYRE) is a biotechnology company developing treatments for inflammatory bowel disease. The company is currently focused on its drug candidate, SPY001, which is being tested as a potential treatment for moderate-to-severe ulcerative colitis, a chronic inflammatory condition affecting the large intestine.

Following positive trial results, Deutsche Bank raises its price target on Spyre Therapeutics to $88.00, a significant increase from its previous target of $55.00. This new target suggests a potential upside of approximately 39.09% from the stock's price of $63.27 at the time of the announcement.

The analyst's confidence comes after Spyre Therapeutics announced successful results from its Phase 2 SKYLINE trial. As highlighted by GlobeNewswire, the trial met its primary goal. It showed a statistically significant 9.2-point reduction in the Robart's Histopathology Index (RHI) score, a measure of disease activity, at week 12.

The trial also achieved key secondary goals, with 40% of patients reaching clinical remission and 51% showing endoscopic improvement. Benzinga highlights that this positive data has caused the stock to trade higher. The company reports that SPY001 was well-tolerated by patients during the study.

The market has reacted strongly to the news. The stock's price has risen by 23.36% in a single day, reaching a new 52-week high of $75.00. The company's market capitalization, which is the total value of all its shares, now stands at approximately $3.82 billion.